• April 6, 2021

In the forward, Michelle Cloutier, MD, Chair, Expert Panel Working Group, indicated “there is an ‘absence of many strong recommendations,’ which are those recommendations that clinicians should adhere to almost all the time as standard of care. ‘This is not, however, surprising given the variations in asthma phenotypes and endotypes and in the outcomes used […]

  • February 10, 2021

When repurposing oral or parenteral therapies for inhaled administration, there are a number of important factors to evaluate early in the drug development process. Considering these factors may increase chances that a repurposed product could be positioned for successful clinical studies and commercial adoption by patients. A key question is, “Why are we repurposing the […]

Current therapies for pulmonary arterial hypertension do not provide a cure and their use can be limited due to systemic side effects. Consequently, there is a critical need to discover and develop new drugs that target vascular remodeling and provide long-term disease reversal benefits. Drug repurposing can bypass common challenges of drug discovery and offer […]

  • December 1, 2020

The author provides a brief history of nasal delivery devices and their applications then look to potential uses in the future. Article topics include: device platforms, locally acting products, vaccines, systemic nasal drug delivery, patient considerations, regulatory considerations and future opportunities. In addition, the article includes a table listing samples of US FDA-approved nasal products […]

The Asthma and Allergy Foundation of America (AAFA) has published the report, “Asthma Disparities in America: A Roadmap to Reducing Burden on Racial and Ethnic Minorities.” The report discusses “serious gaps in asthma rates, care and outcomes” and is follow-up to AAFA’s 2005 report, “Ethnic Disparities in the Burden and Treatment of Asthma.” The new […]

  • September 29, 2020

While regulations currently do not place restrictions on the use of HFA-134a or HFA-227ea for pressurized metered dose inhalers, they have the potential to adversely impact the supply chain through rationing or loss of industrial product feedstocks used as inputs for medical product manufacturing. Further, individuals and companies are seeking ways to reduce their environmental […]

As the COVID-19 pandemic began, it was commonly believed that patients with asthma would be at increased risk for severe symptoms, hospitalization and mortality. Surprisingly, “a growing body of research that suggests that the link between COVID-19 and asthma is far more complex than experts might have anticipated.” A small number of studies have shown […]

  • August 4, 2020

The authors suggest that impaction data is fundamentally flawed and ineffective because individual stage groupings do not adequately account for both dimensions of the size-fractionated mass comprising the APSD, and their combined use compounds this weakness to dramatic effect. Clearly, they say, stage groupings cannot be relied upon for batch-disposition decisions and are therefore a […]

  • June 2, 2020

It is in the best interest of all key stakeholders to have inhaled medications accessible and affordable to all who need them. At the same time, it is necessary to continue to reward companies and individuals who work with innovator products for their efforts and investments that bring better inhaled medications to patients. Both innovator […]

Now, more than ever, healthcare economics are providing the impetus for innovation and consequently we will see some non-obvious disease states being treated using the nasal route. As we better understand the relationships of particle size, delivered gas, patient anatomy, and inspiratory patterns across patient populations, we expect more optimized pulmonary delivery efficiency, expanding trans-nasal […]